Clinical Trial Update: Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety, tolerability, and efficacy of secukinumab in moderate to severe palmoplantar psoriasis; study completed with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Palmoplantar Psoriasis
• Psoriasis Vulgaris

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Moderate to Severe Palmoplantar Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2018-02-22